Literature DB >> 2319168

Administration of recombinant interleukin-2 reduces the local parasite load of patients with disseminated cutaneous leishmaniasis.

H Akuffo1, G Kaplan, R Kiessling, S Teklemariam, M Dietz, J McElrath, Z A Cohn.   

Abstract

Three patients with disseminated cutaneous leishmaniasis received three intranodular injections of 10 micrograms of recombinant interleukin 2 (rIL-2) at 48-h intervals. After 7 and 14 days, 4-mm punch biopsies were taken of control and injected nodules and processed for histology, electron microscopy, immunocytochemistry, and parasite culture. Control sites exhibited loose infiltrates of parasitized macrophages and T cells predominantly of the CD8+ phenotype. Amastigotes were present in large numbers and were found distributed within tightly apposed endosomes and larger vacuoles. After the administration of rIL-2, there was a prominent influx of T cells, predominantly of the CD4+ phenotype, and an increased number of plasma cells. At 7 days, leishmanial amastigotes were present in either the same or somewhat reduced numbers but predominantly within large, lucent vacuoles. By 14 days the number of amastigotes was strikingly lower. Lymphokine-treated skin sites became sterile in two patients, as evaluated by parasite culture after rIL-2 injection. The results suggest that the local administration of rIL-2 induces a beneficial enhancement of the cellular immunity with a consequent disposal of parasites in the cutaneous site.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2319168     DOI: 10.1093/infdis/161.4.775

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  5 in total

1.  Old World cutaneous leishmaniasis: diagnosis and treatment.

Authors:  Abderrahmen Masmoudi; Wala Hariz; Slaheddine Marrekchi; Mariem Amouri; Hamida Turki
Journal:  J Dermatol Case Rep       Date:  2013-06-30

2.  Interleukin 2 is an Upstream Regulator of CD4+ T Cells From Visceral Leishmaniasis Patients With Therapeutic Potential.

Authors:  Shashi Bhushan Chauhan; Rebecca Faleiro; Rajiv Kumar; Susanna Ng; Bhawana Singh; Om Prakash Singh; Siddharth Sankar Singh; Fiona Amante; Fabian de Labastida Rivera; Madhukar Rai; Jaya Chakravarty; David Sacks; Susanne Nylen; Shyam Sundar; Christian Engwerda
Journal:  J Infect Dis       Date:  2019-06-05       Impact factor: 5.226

3.  Therapeutic effects of recombinant human interleukin 2 as adjunctive immunotherapy against tuberculosis: A systematic review and meta-analysis.

Authors:  Ruimei Zhang; Xiangyu Xi; Chunying Wang; Yong Pan; Changhua Ge; Liying Zhang; Shuo Zhang; Huimei Liu
Journal:  PLoS One       Date:  2018-07-19       Impact factor: 3.240

4.  Single nucleotide polymorphisms of the genes IL-2, IL-2RB, and JAK3 in patients with cutaneous leishmaniasis caused by Leishmania (V.) guyanensis in Manaus, Amazonas, Brazil.

Authors:  Felipe Jules de Araújo Santos; Lener Santos da Silva; José do Espírito Santo Júnior; Tirza Gabrielle Ramos de Mesquita; Mara Lúcia Gomes de Souza; Moacir Couto de Andrade Júnior; Sinésio Talhari; Rajendranath Ramasawmy
Journal:  PLoS One       Date:  2019-08-08       Impact factor: 3.240

5.  Zanvil Alexander Cohn 1926-1993.

Authors:  R M Steinman; C L Moberg
Journal:  J Exp Med       Date:  1994-01-01       Impact factor: 14.307

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.